Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Multiple statements are not supported by the provided FDA label excerpts (notably hypertension-related claims). Some epilepsy/brand and side-effect/interaction assertions are not supported or cannot be verified from the supplied text, and therefore substantially reduce alignment.
Category Scores
Accurate Statements
Lacosamide is primarily used to treat epilepsy.
Supported in general terms by the label indication for seizures (Section 1.1/1.2 partial-onset seizures and primary generalized tonic-clonic seizures).
Lacosamide is an antiepileptic drug.
Supported by the label referring to VIMPAT as an antiepileptic drug (implicit in Warnings and the term AEDs used with VIMPAT).
Lacosamide is available under the brand name Vimpat.
Supported by label excerpts using the brand name VIMPAT (active ingredient lacosamide).
Lacosamide is prescribed for the treatment of partial-onset seizures in adults and children.
Supported: VIMPAT is indicated for partial-onset seizures in patients 1 month of age and older (Section 1.1).
Unsupported Statements
Lacosamide works by stabilizing abnormal electrical activity in the brain, thereby reducing the frequency and severity of seizures.
No such mechanism/wording is provided in the supplied label excerpts.
Lacosamide is prescribed for the treatment of partial-onset seizures in adults and children.
While partial-onset indication is supported, the label excerpt specifies age 1 month of age and older; the statement does not incorporate the exact labeled age threshold (adults and children is broadly consistent but not label-exact).
Some studies have suggested that lacosamide may have a potential role in the treatment of secondary hypertension.
Not supported by any provided label excerpts; the label sections shown do not mention hypertension.
Research has shown that lacosamide may have a beneficial effect on blood pressure in patients with hypertension, particularly those with resistant hypertension.
Not supported by provided label excerpts.
The exact mechanism by which lacosamide affects blood pressure is not fully understood.
Not supported by provided label excerpts.
Lacosamide is thought to be related to its effects on the sympathetic nervous system.
Not supported by provided label excerpts.
Lacosamide may help to reduce sympathetic nervous system activity, which can lead to a decrease in blood pressure.
Not supported by provided label excerpts.
A study in the Journal of Clinical Hypertension found that lacosamide significantly reduced blood pressure in patients with resistant hypertension.
Not supported by provided label excerpts.
A study in the European Journal of Clinical Pharmacology found that lacosamide had a beneficial effect on blood pressure in patients with hypertension, particularly those with kidney disease.
Not supported by provided label excerpts.
Lacosamide can cause side effects including dizziness, headache, and nausea.
The label excerpt lists serious adverse reactions (e.g., dizziness and ataxia), but does not provide support for headache and nausea specifically in the supplied text.
Lacosamide may interact with other medications, including blood thinners and certain antidepressants.
The supplied label excerpt describes interactions related to strong CYP3A4/CYP2C9 inhibitors and concomitant medications affecting cardiac conduction, but does not mention blood thinners or antidepressants.
Contradictions
Important Omissions
Approved indications beyond partial-onset seizures (e.g., adjunctive therapy for primary generalized tonic-clonic seizures in patients 4 years of age and older).
Importance:
Low
Key safety warnings present in the provided label excerpts (e.g., suicidal behavior/ideation, withdrawal gradually, DRESS/multi-organ hypersensitivity, syncope).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported hypertension-related claims and unsupported/unspecified interaction statements could mislead clinical use. Additionally, incomplete alignment with label safety warnings reduces reliability.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Unaligned
Primary Issue
Hypertension/blood pressure claims and interaction specifics (blood thinners/antidepressants) are not supported by the provided VIMPAT label excerpts; mechanism and side-effect details are also not fully supported.
Suggested Improvement
Limit claims to information supported by the provided label excerpts (approved seizure indications, labeled warnings/precautions such as suicidal behavior/ideation and cardiac conduction abnormalities, and interactions as described: CYP3A4/CYP2C9 strong inhibitors and concomitant cardiac conduction–affecting medications). Remove or qualify hypertension-related content and interaction classes not present in the label excerpts.